ArticleMetabolic brain disease2025
Investigating cuproptosis and mitochondrial dysfunction in brain cells: uncovering novel mechanisms and biomarkers for Parkinson's disease.
Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nrf2 Activators in Parkinson's Disease: Modulating Mitophagy and Regulating Cuproptosis.Molecular neurobiology · 2026Review
- Gut microbiota reconstitution and control of α-synucleinopathy with β-glucans: a promising approach for individuals with parkinson's disease.Metabolic brain disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a chronic neurodegenerative condition marked by the gradual degeneration of dopaminergic neurons, resulting in a range of disabling motor and non-motor symptoms. Despite advances, the molecular mechanisms underlying PD remain elusive, and effective biomarkers and therapeutic targets are limited. Recent studies suggest that mitochondrial dysfunction and dysregulated cellular metabolism are central to PD pathogenesis. This study investigated cuproptosis-related genes (CRGs), a class of genes linked to mitochondrial function and metabolic pathways, as potential contributors to PD using in silico and in vitro analyses. By analyzing Gene Expression Omnibus (GEO) datasets, we identified a consistent downregulation of CRGs, including DLD, FDX1, LIPT1, LIAS, PDHB, DLAT, PDHA1, CDKN2A, MTF1, and GLS, in PD samples. Immune infiltration analysis and subcellular localization studies highlighted significant correlations with immune cells and mitochondrial localization, implicating CRGs in immune and metabolic dysregulation. Functional assays confirmed that overexpression of DLD and FDX1 promotes cell proliferation and migration, suggesting their involvement in PD progression. Diagnostic model analysis further demonstrated the strong potential of CRGs as biomarkers, with high Area Under the Curve (AUC) values indicating accuracy in distinguishing PD from controls. Additionally, miRNA-mRNA interaction and drug sensitivity analyses identified key regulatory microRNAs (miRNAs) and drug sensitivities associated with CRGs expression. Pathway enrichment analysis linked CRGs to essential mitochondrial and metabolic processes, providing insights into PD's underlying mechanisms. The findings of this study emphasize the diagnostic and therapeutic potential of CRGs in PD, offering a novel avenue for understanding and managing this complex disease.
Indexed as
Identifiers
40072691What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.